FY2025 EPS Estimates for Sanara MedTech Boosted by Analyst

Key Points

• Analysts at Cantor Fitzgerald raised their FY2025 EPS estimates for Sanara MedTech to ($0.88) per share, significantly up from a previous estimate of ($1.78).
• HC Wainwright increased its price target on Sanara MedTech from $51.00 to $53.00, maintaining a "buy" rating for the stock.
• Institutional investors, including Marshall Wace LLP and Renaissance Technologies LLC, have substantially increased their stakes in Sanara MedTech, indicating growing confidence in the company's prospects.

Sanara MedTech Inc. (NASDAQ:SMTI - Free Report) - Analysts at Cantor Fitzgerald boosted their FY2025 EPS estimates for shares of Sanara MedTech in a research note issued to investors on Thursday, August 14th. Cantor Fitzgerald analyst R. Osborn now expects that the company will post earnings of ($0.88) per share for the year, up from their prior forecast of ($1.78). The consensus estimate for Sanara MedTech's current full-year earnings is ($1.10) per share. Cantor Fitzgerald also issued estimates for Sanara MedTech's FY2026 earnings at ($0.16) EPS.

Separately, HC Wainwright upped their target price on shares of Sanara MedTech from $53.00 to $54.00 and gave the company a "buy" rating in a research note on Monday. Two research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $50.00.

Sanara MedTech Price Performance

NASDAQ SMTI traded down $0.23 on Monday, reaching $30.50. The company's stock had a trading volume of 23,632 shares, compared to its average volume of 33,965. The firm has a market cap of $271.45 million, a PE ratio of -26.36 and a beta of 1.26. The business has a 50-day moving average price of $27.78 and a 200 day moving average price of $30.38. Sanara MedTech has a 52 week low of $23.53 and a 52 week high of $39.08. The company has a current ratio of 2.26, a quick ratio of 2.03 and a debt-to-equity ratio of 1.25.

Sanara MedTech (NASDAQ:SMTI - Get Free Report) last announced its quarterly earnings data on Wednesday, August 13th. The company reported ($0.23) EPS for the quarter, beating analysts' consensus estimates of ($0.33) by $0.10. The business had revenue of $25.83 million during the quarter, compared to analyst estimates of $25.15 million. Sanara MedTech had a negative net margin of 10.22% and a negative return on equity of 26.43%.

Institutional Trading of Sanara MedTech

Several hedge funds have recently modified their holdings of the stock. Northern Trust Corp grew its stake in shares of Sanara MedTech by 0.9% during the fourth quarter. Northern Trust Corp now owns 40,816 shares of the company's stock valued at $1,355,000 after purchasing an additional 358 shares during the last quarter. Rhumbline Advisers lifted its holdings in Sanara MedTech by 14.9% in the first quarter. Rhumbline Advisers now owns 3,714 shares of the company's stock valued at $115,000 after buying an additional 483 shares during the period. Wells Fargo & Company MN lifted its holdings in Sanara MedTech by 53.9% in the fourth quarter. Wells Fargo & Company MN now owns 1,893 shares of the company's stock valued at $63,000 after buying an additional 663 shares during the period. Barclays PLC lifted its holdings in Sanara MedTech by 12.1% in the fourth quarter. Barclays PLC now owns 6,423 shares of the company's stock valued at $213,000 after buying an additional 692 shares during the period. Finally, Bank of New York Mellon Corp lifted its holdings in Sanara MedTech by 6.3% in the first quarter. Bank of New York Mellon Corp now owns 13,880 shares of the company's stock valued at $428,000 after buying an additional 826 shares during the period. 8.10% of the stock is owned by institutional investors.

Sanara MedTech Company Profile

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.